State-of-the-art strategies for targeting the DNA damage response in cancer
- PMID: 30356138
- PMCID: PMC8327299
- DOI: 10.1038/s41571-018-0114-z
State-of-the-art strategies for targeting the DNA damage response in cancer
Abstract
Genomic instability is a key hallmark of cancer that arises owing to defects in the DNA damage response (DDR) and/or increased replication stress. These alterations promote the clonal evolution of cancer cells via the accumulation of driver aberrations, including gene copy-number changes, rearrangements and mutations; however, these same defects also create vulnerabilities that are relatively specific to cancer cells, which could potentially be exploited to increase the therapeutic index of anticancer treatments and thereby improve patient outcomes. The discovery that BRCA-mutant cancer cells are exquisitely sensitive to inhibition of poly(ADP-ribose) polymerase has ushered in a new era of research on biomarker-driven synthetic lethal treatment strategies for different cancers. The therapeutic landscape of antitumour agents targeting the DDR has rapidly expanded to include inhibitors of other key mediators of DNA repair and replication, such as ATM, ATR, CHK1 and CHK2, DNA-PK and WEE1. Efforts to optimize these therapies are ongoing across a range of cancers, involving the development of predictive biomarker assays of responsiveness (beyond BRCA mutations), assessment of the mechanisms underlying intrinsic and acquired resistance, and evaluation of rational, tolerable combinations with standard-of-care treatments (such as chemotherapeutics and radiation), novel molecularly targeted agents and immune-checkpoint inhibitors. In this Review, we discuss the current status of anticancer therapies targeting the DDR.
Conflict of interest statement
Competing interests
The other authors declare no competing interests.
Figures
![FIG. 1 |](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/8327299/bin/nihms-1727396-f0001.gif)
![FIG. 2 |](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/8327299/bin/nihms-1727396-f0002.gif)
![FIG. 3 |](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/8327299/bin/nihms-1727396-f0003.gif)
![FIG. 4 |](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/8327299/bin/nihms-1727396-f0004.gif)
Similar articles
-
Therapeutic Targeting of DNA Damage Response in Cancer.Int J Mol Sci. 2022 Feb 1;23(3):1701. doi: 10.3390/ijms23031701. Int J Mol Sci. 2022. PMID: 35163621 Free PMC article. Review.
-
The DNA Damaging Revolution: PARP Inhibitors and Beyond.Am Soc Clin Oncol Educ Book. 2019 Jan;39:185-195. doi: 10.1200/EDBK_238473. Epub 2019 May 17. Am Soc Clin Oncol Educ Book. 2019. PMID: 31099635 Review.
-
Biomarkers of Response and Resistance to DNA Repair Targeted Therapies.Clin Cancer Res. 2016 Dec 1;22(23):5651-5660. doi: 10.1158/1078-0432.CCR-16-0247. Epub 2016 Sep 27. Clin Cancer Res. 2016. PMID: 27678458 Review.
-
Targeting DNA Repair in Cancer: Beyond PARP Inhibitors.Cancer Discov. 2017 Jan;7(1):20-37. doi: 10.1158/2159-8290.CD-16-0860. Epub 2016 Dec 21. Cancer Discov. 2017. PMID: 28003236 Free PMC article. Review.
-
Targeting the DNA damage response beyond poly(ADP-ribose) polymerase inhibitors: novel agents and rational combinations.Curr Opin Oncol. 2022 Sep 1;34(5):559-569. doi: 10.1097/CCO.0000000000000867. Epub 2022 Jul 5. Curr Opin Oncol. 2022. PMID: 35787597 Free PMC article. Review.
Cited by
-
Baseline DSB repair prediction of chronic rare Grade ≥ 3 toxicities induced by radiotherapy using classification algorithms.J Radiat Res. 2024 Jul 22;65(4):540-548. doi: 10.1093/jrr/rrae047. J Radiat Res. 2024. PMID: 38899572 Free PMC article.
-
Mutation characteristics of cancer susceptibility genes in Chinese ovarian cancer patients.Front Oncol. 2024 May 16;14:1395818. doi: 10.3389/fonc.2024.1395818. eCollection 2024. Front Oncol. 2024. PMID: 38817903 Free PMC article.
-
Rapid P-TEFb-dependent transcriptional reorganization underpins the glioma adaptive response to radiotherapy.Nat Commun. 2024 May 30;15(1):4616. doi: 10.1038/s41467-024-48214-3. Nat Commun. 2024. PMID: 38816355 Free PMC article.
-
A negative feedback loop underlies the Warburg effect.NPJ Syst Biol Appl. 2024 May 24;10(1):55. doi: 10.1038/s41540-024-00377-x. NPJ Syst Biol Appl. 2024. PMID: 38789545 Free PMC article.
-
Epigenetic silencing schlafen-11 sensitizes esophageal cancer to ATM inhibitor.World J Gastrointest Oncol. 2024 May 15;16(5):2060-2073. doi: 10.4251/wjgo.v16.i5.2060. World J Gastrointest Oncol. 2024. PMID: 38764821 Free PMC article.
References
-
- Roos WP, Thomas AD & Kaina B. DNA damage and the balance between survival and death in cancer biology. Nat. Rev. Cancer 16, 20–33 (2016). - PubMed
-
- Xu Y. DNA damage: a trigger of innate immunity but a requirement for adaptive immune homeostasis. Nat. Rev. Immunol. 6, 261–270 (2006). - PubMed
-
- Hanahan D & Weinberg RA Hallmarks of cancer: the next generation. Cell 144, 646–674 (2011). - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous